Program
tucidinostat
Also written as “Chidamide”, “Tucidinostat” and “HBI-8000”.
Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Melanoma · Breast Neoplasms · Lymphoma, Non-Hodgkin, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chipscreen Biosciences | 92 open or running | phase 3since Jun 17, 2015 | Apr 12, 2013 | May 31, 2028phase 3 · NCT06497985 |
| HUYABIO International, LLC. | 71 open or running | phase 3since Dec 7, 2020 | Oct 5, 2015 | none ahead |
| Great Novel Therapeutics Biotech & Medicals | 21 open or running | phase 2since Feb 7, 2023 | Feb 7, 2023 | Jun 2027phase 2 · NCT05833724 |
| Jiangsu HengRui Medicine | 11 open or running | phase 3since Nov 5, 2023 | Nov 5, 2023 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb and iqvia-pty-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Apr 12, 2013.
- Mar 15, 2016Phase 2 study in MelanomaHUYABIO International, LLC. · NCT02718066 · 96 enrolled · United States
- Jun 17, 2016Phase 1 study in Lymphoma, T-Cell, PeripheralChipscreen Biosciences · NCT02809573 · 30 enrolled · China
- Nov 1, 20162 phase 2 studiesHUYABIO International, LLC. · NCT02955589, NCT02953652
- May 30, 2019Phase 2 study in Lymphoma, Non-HodgkinChipscreen Biosciences · NCT03974243 · 9 enrolled · China
- Jan 14, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseChipscreen Biosciences · NCT04231448 · 423 enrolled · China
- Dec 7, 2020Phase 3 study in MelanomaHUYABIO International, LLC. · NCT04674683 · 450 enrolled · United States, Australia, Austria and more
- Sep 27, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungChipscreen Biosciences · NCT05068427 · 34 enrolled · China
- Nov 19, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungHUYABIO International, LLC. · NCT05141357 · 5 enrolled · United States
- Aug 23, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungChipscreen Biosciences · NCT05519865 · 118 enrolled · China
- Feb 7, 2023Great Novel Therapeutics Biotech & Medicals's first study: phase 2 study in Carcinoma, HepatocellularNew to Great Novel Therapeutics Biotech & MedicalsGreat Novel Therapeutics Biotech & Medicals · NCT05770882 · 7 enrolled · Taiwan
- Apr 17, 2023Phase 2 study in RecurrenceGreat Novel Therapeutics Biotech & Medicals · NCT05833724 · 33 planned · Taiwan
- Nov 5, 2023Jiangsu HengRui Medicine's first study: phase 3 study in RecurrenceNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06122389 · 130 planned · China
- Jun 28, 2024Phase 3 study in Colorectal NeoplasmsChipscreen Biosciences · NCT06497985 · 430 planned · China
- Apr 25, 2025Phase 3 study in Lymphoma, T-Cell, PeripheralChipscreen Biosciences · NCT06947967 · 224 planned · China
Ahead
- Jun 2027Primary completion: phase 2 study in RecurrenceGreat Novel Therapeutics Biotech & Medicals · NCT05833724
- May 31, 2028Primary completion: phase 3 study in Colorectal NeoplasmsChipscreen Biosciences · NCT06497985
- Dec 2032Primary completion: phase 3 study in Lymphoma, T-Cell, PeripheralChipscreen Biosciences · NCT06947967
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06947967Lymphoma, T-Cell, Peripheral · China | 3 | Recruiting | Chipscreen Biosciences | Dec 2032 | 224 |
| NCT06497985Colorectal Neoplasms · China | 3 | Recruiting | Chipscreen Biosciences | May 31, 2028 | 430 |
| NCT06122389Recurrence · China | 3 | Recruiting | Jiangsu HengRui Medicine | May 2026 | 130 |
| NCT05833724Recurrence · Taiwan | 2 | Recruiting | Great Novel Therapeutics Biotech & Medicals | Jun 2027 | 33 |
| NCT05770882Carcinoma, Hepatocellular · Taiwan | 2 | Terminated | Great Novel Therapeutics Biotech & Medicals | Jan 17, 2025 | 7 |
| NCT05519865Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Chipscreen Biosciences | Nov 18, 2024 | 118 |
| NCT05141357Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | HUYABIO International, LLC. | Apr 19, 2023 | 5 |
| NCT05068427Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Chipscreen Biosciences | Feb 23, 2023 | 34 |
| NCT04674683Melanoma · United States, Australia, Austria and more | 3 | Active, not recruiting | HUYABIO International, LLC. | Jul 2026 | 450 |
| NCT04231448Lymphoma, Large B-Cell, Diffuse · China | 3 | Completed | Chipscreen Biosciences | Jan 10, 2023 | 423 |
| NCT03974243Lymphoma, Non-Hodgkin · China | 2 | Completed | Chipscreen Biosciences | Dec 31, 2021 | 9 |
| NCT02955589Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Japan | 2 | Completed | HUYABIO International, LLC. | Dec 2018 | 23 |
| NCT02953652Lymphoma, T-Cell, Peripheral · Japan, Korea, Republic of | 2 | Completed | HUYABIO International, LLC. | Feb 17, 2022 | 55 |
| NCT02809573Lymphoma, T-Cell, Peripheral · China | 1 | Completed | Chipscreen Biosciences | Jan 8, 2019 | 30 |
| NCT02718066Melanoma · United States | 2 | Completed | HUYABIO International, LLC. | Dec 12, 2023 | 96 |
| NCT02697552Lymphoma, Non-Hodgkin · Japan | 1 | Completed | HUYABIO International, LLC. | Oct 2016 | 13 |
| NCT02569489Breast Neoplasms | 1 | Withdrawn | HUYABIO International, LLC. | Dec 2015 | 0 |
| NCT02482753Breast Neoplasms · China | 3 | Completed | Chipscreen Biosciences | Mar 2018 | 365 |
| NCT01836679Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Chipscreen Biosciences | May 2015 | 124 |
How it is read
Names in the registry
- “Chidamide”, 7 entries
- “Tucidinostat”, 4 entries
- “HBI-8000”, 4 entries
- “HBI-8000 in combination with nivolumab”, 2 entries
- “SHR2554 analog tablets; Chidamide”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, Peripheral, 4 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Melanoma, 2 studies
- Breast Neoplasms, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.